Were you injured by a weight loss drug?

Ozempic

Semaglutide · Novo Nordisk

## What is Ozempic? Ozempic (semaglutide) is a once-weekly injectable prescription medication manufactured by Novo Nordisk. It was initially approved by the FDA in 2017 for the treatment of type 2 diabetes mellitus. The medication belongs to a class of drugs called GLP-1 (glucagon-like peptide-1) receptor agonists, which work by mimicking the effects of a naturally occurring hormone that regulates blood sugar levels and appetite. ## How Ozempic Works Ozempic works by stimulating insulin secretion when blood sugar levels are high, suppressing glucagon production, and slowing gastric emptying. It is this last effect — slowing the movement of food through the stomach — that has been linked to serious gastrointestinal injuries in some patients. ## The Link to Severe Injuries While Ozempic has been effective for many patients in managing blood sugar and promoting weight loss, it has been associated with severe, sometimes permanent injuries: - **Gastroparesis**: Also known as stomach paralysis, this condition causes food to remain in the stomach for extended periods, leading to severe nausea, vomiting, bloating, and malnutrition. In some cases, the condition is irreversible. - **Pancreatitis**: Inflammation of the pancreas that can be life-threatening and may require hospitalization. - **Bowel Obstruction**: Complete or partial blockage of the intestines that may require surgical intervention. - **Gallbladder Disease**: Including gallstones and inflammation that may require surgical removal of the gallbladder. ## Legal Claims Against Novo Nordisk Thousands of patients who suffered injuries from Ozempic have filed lawsuits against Novo Nordisk, alleging that the company failed to adequately warn about the risks of gastroparesis and other severe gastrointestinal side effects. These claims are being consolidated into multi-district litigation (MDL) to streamline the legal process. If you or a loved one took Ozempic and developed gastroparesis, pancreatitis, or another serious injury, you may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages.

Wegovy

Semaglutide · Novo Nordisk

## What is Wegovy? Wegovy (semaglutide) is a once-weekly injectable prescription medication approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight conditions. Manufactured by Novo Nordisk, Wegovy contains the same active ingredient as Ozempic — semaglutide — but at a higher dose specifically formulated for weight loss. ## How Wegovy Works Like Ozempic, Wegovy is a GLP-1 receptor agonist that works by mimicking the effects of the naturally occurring GLP-1 hormone. It suppresses appetite, slows gastric emptying, and helps regulate blood sugar. The higher dose of semaglutide in Wegovy means patients may be exposed to an even greater risk of gastrointestinal side effects. ## Severe Injuries Associated with Wegovy Patients taking Wegovy have reported serious, sometimes life-altering injuries: - **Gastroparesis**: Stomach paralysis that can cause severe nausea, vomiting, and malnutrition. Some patients require feeding tubes or gastric pacemakers. - **Pancreatitis**: Inflammation of the pancreas that can be life-threatening and may cause permanent organ damage. - **Bowel Obstruction**: Blockage of the intestines that may require emergency surgery. - **Gallbladder Disease**: Gallstones and inflammation that frequently require surgical removal of the gallbladder. - **Thyroid Tumors**: Including medullary thyroid carcinoma, a rare but serious form of thyroid cancer. ## Legal Claims Against Novo Nordisk Wegovy lawsuits are being filed alongside Ozempic claims, as both medications contain the same active ingredient. Plaintiffs allege that Novo Nordisk knew or should have known about the risks of severe gastrointestinal injuries but failed to adequately warn patients and healthcare providers. The consolidation of Wegovy and Ozempic cases into multi-district litigation is expected to streamline the legal process and establish precedent for future claims.

Mounjaro

Tirzepatide · Eli Lilly

## What is Mounjaro? Mounjaro (tirzepatide) is a once-weekly injectable prescription medication manufactured by Eli Lilly and Company. Approved by the FDA in 2022 for the treatment of type 2 diabetes, Mounjaro is the first in a new class of drugs called dual GIP/GLP-1 receptor agonists. It works by activating both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. ## How Mounjaro Works Mounjaro's dual-action mechanism stimulates insulin production, reduces glucagon secretion, and slows gastric emptying — more aggressively than single-action GLP-1 agonists. This enhanced effect on gastric emptying may contribute to a higher risk of gastrointestinal injuries. ## Severe Injuries Associated with Mounjaro Patients taking Mounjaro have reported serious adverse events: - **Pancreatitis**: Acute inflammation of the pancreas that can be life-threatening and may cause permanent damage. - **Thyroid Tumors**: Including medullary thyroid carcinoma, a rare but serious cancer. - **Gastroparesis**: Stomach paralysis causing severe nausea, vomiting, and inability to digest food properly. - **Gallbladder Disease**: Gallstones and inflammation that may require surgical removal. - **Kidney Failure**: Acute kidney injury, sometimes requiring dialysis. ## Legal Claims Against Eli Lilly Lawsuits have been filed against Eli Lilly alleging that the company failed to adequately warn patients and healthcare providers about the risks of pancreatitis, thyroid tumors, and other severe side effects associated with Mounjaro. As the medication is relatively new, litigation is in early stages but is expected to grow significantly.

Saxenda

Liraglutide · Novo Nordisk

## What is Saxenda? Saxenda (liraglutide) is a daily injectable prescription medication approved by the FDA in 2014 for chronic weight management. Manufactured by Novo Nordisk, Saxenda was one of the first GLP-1 receptor agonists specifically approved for weight loss rather than diabetes management. ## How Saxenda Works Saxenda works by mimicking the GLP-1 hormone, which regulates appetite and food intake. Like other GLP-1 agonists, it also slows gastric emptying, which can contribute to gastrointestinal side effects. Unlike the weekly formulations of Ozempic and Wegovy, Saxenda requires daily injections. ## Severe Injuries Associated with Saxenda Patients taking Saxenda have reported serious, sometimes permanent injuries: - **Pancreatitis**: Inflammation of the pancreas that can be life-threatening and may cause permanent organ damage. - **Gallbladder Disease**: A significant percentage of Saxenda patients develop gallstones or gallbladder inflammation, frequently requiring surgical removal of the gallbladder (cholecystectomy). - **Thyroid C-cell Tumors**: Including medullary thyroid carcinoma, a rare but serious form of thyroid cancer. - **Kidney Failure**: Acute kidney injury, sometimes requiring dialysis. - **Severe Gastrointestinal Issues**: Including persistent nausea, vomiting, and diarrhea. ## Legal Claims Against Novo Nordisk Saxenda lawsuits have been filed against Novo Nordisk alleging that the company failed to adequately warn about the risks of pancreatitis, gallbladder disease, and thyroid tumors. Many patients required gallbladder removal surgery, a procedure with lifelong implications for digestion and diet. Cases are being consolidated in multi-district litigation to streamline the legal process.

How to Document Your Weight Loss Drug Injury for a Lawsuit

Step-by-step guide to preserving medical evidence, pharmacy records, and physician documentation for a strong legal claim.

Wegovy vs. Ozempic: Legal Claims and Key Differences

Comparative legal analysis of Wegovy and Ozempic litigation, shared active ingredients, and distinct claim strategies.

GLP-1 Lawsuit Eligibility: Statute of Limitations by State

State-by-state breakdown of filing deadlines for weight loss drug injury claims. Don't miss your window to file.